Is Bimzelx Approved for Psoriasis?
No, Bimzelx (bimekizumab-bkzx) is not approved or indicated for plaque psoriasis (PsA often refers to psoriatic arthritis, but psoriasis is PsO; assuming psoriasis here based on common shorthand). It targets moderate-to-severe plaque psoriasis specifically, with FDA approval in October 2023 for adults eligible for systemic therapy or phototherapy.[1]
What Is Bimzelx Actually Approved For?
Bimzelx, made by UCB, is a monoclonal antibody that blocks IL-17A and IL-17F cytokines. Current FDA approvals include:
- Plaque psoriasis (adults, 2023).
- Psoriatic arthritis (adults, 2024).
- Axial spondyloarthritis (adults, 2024).
- Hidradenitis suppurativa (adults, expected 2025 pending approval).[1][2]
It reduces inflammation in these IL-17-driven conditions but is not labeled for non-plaque psoriasis variants like guttate or pustular without systemic involvement.
Is Bimzelx Used Off-Label for Other Psoriasis Types?
Off-label use occurs rarely due to its plaque psoriasis focus and high cost (~$6,000/month). Phase 3 trials showed efficacy in plaque psoriasis (PASI 90 response in 60% at week 16), but data for generalized pustular psoriasis (GPP) or other forms is limited to smaller studies.[3] Dermatologists sometimes consider it for refractory cases, but guidelines prioritize other biologics like IL-23 inhibitors first.
How Does Bimzelx Compare to Psoriasis Treatments Like Stelara or Skyrizi?
| Drug | Target | Psoriasis Approval | Dosing | Key Psoriasis Data |
|------|--------|---------------------|--------|--------------------|
| Bimzelx | IL-17A/F | Plaque (2023) | Q4-8 weeks | PASI 90: 60% at 16 weeks[3] |
| Stelara (ustekinumab) | IL-12/23 | Plaque, PsA (2009) | Q12 weeks | PASI 90: 37% at 12 weeks |
| Skyrizi (risankizumab) | IL-23 | Plaque, PsA (2019) | Q12 weeks | PASI 100: 44% at 16 weeks |
Bimzelx clears skin faster than older IL-17 blockers like Cosentyx but has more injection-site reactions (15-20%).[3]
When Could Bimzelx Expand Indications or Face Competition?
Patents protect Bimzelx until ~2036 (core composition patent expires 2035-2040 depending on extensions; check DrugPatentWatch.com for litigation updates).[4] Biosimilars unlikely before 2037. Upcoming trials test it in non-radiographic axial spondyloarthritis and pediatric psoriasis, potentially broadening use by 2026.
Common Patient Questions on Bimzelx for Psoriasis
- Side effects? Oral candidiasis (10-15%), upper respiratory infections; monitor for IBD flare risk.[1]
- Cost and access? List price $6,174/dose; copay cards reduce to $5/month for eligible patients.
- Who shouldn't use it? Active IBD, untreated infections, or hypersensitivity.
[1]: FDA Label - Bimzelx (bimekizumab-bkzx). https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761032s000lbl.pdf
[2]: UCB Press Release, PsA Approval (2024). https://www.ucb.com/newsroom/press-releases/article/UCB-receives-US-FDA-approval-for-BIMZELX-bimekizumab-bkzx-for-the-treatment-of-adults-with-active-psoriatic-arthritis
[3]: BE VIVID/BE READY Trials, NEJM (2021). https://www.nejm.org/doi/full/10.1056/NEJMoa2102373
[4]: DrugPatentWatch - Bimzelx Patents. https://www.drugpatentwatch.com/p/tradename/BIMZELX